Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1989 Aug;73(8):604–607. doi: 10.1136/bjo.73.8.604

Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.

O P van Bijsterveld 1, P J Meurs 1, E de Clercq 1, P C Maudgal 1
PMCID: PMC1041826  PMID: 2669938

Abstract

Bromovinyldeoxyuridine is a potent and safe antiherpes compound that in combination with a placebo treatment promoted the partial and complete healing of herpetic epithelial disease in 22 patients in average times of 4-6 days and 8.5 days respectively. However, when BVDU was combined with 1.5 X 10(6) IU of recombinant a 2C interferon, partial and complete healing times for keratitis in 19 patients were reduced to 2-6 days and 4-6 days respectively. No toxic effects of the medications were observed in any patient.

Full text

PDF
604

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Chen M. S., Lee J. J., De Clercq E., Prusoff W. H. Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells. J Biol Chem. 1982 Jan 25;257(2):603–606. [PubMed] [Google Scholar]
  2. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheng Y. C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol. 1981 Jul;20(1):230–233. [PubMed] [Google Scholar]
  4. Colin J., Chastel C., Renard G., Cantell K. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir. Am J Ophthalmol. 1983 Mar;95(3):346–348. doi: 10.1016/s0002-9394(14)78303-5. [DOI] [PubMed] [Google Scholar]
  5. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2947–2951. doi: 10.1073/pnas.76.6.2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Clercq E., Descamps J., Ogata M., Shigeta S. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother. 1982 Jan;21(1):33–38. doi: 10.1128/aac.21.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  8. De Clercq E. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Antimicrob Chemother. 1984 Aug;14 (Suppl A):85–95. doi: 10.1093/jac/14.suppl_a.85. [DOI] [PubMed] [Google Scholar]
  9. De Clercq E., Walker R. T. Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmacol Ther. 1984;26(1):1–44. doi: 10.1016/0163-7258(84)90049-4. [DOI] [PubMed] [Google Scholar]
  10. Descamps J., De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells. J Biol Chem. 1981 Jun 25;256(12):5973–5976. [PubMed] [Google Scholar]
  11. Fyfe J. A. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol. 1982 Mar;21(2):432–437. [PubMed] [Google Scholar]
  12. Mancini W. R., De Clercq E., Prusoff W. H. The relationship between incorporation of E-5-(2-Bromovinyl)-2'-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. J Biol Chem. 1983 Jan 25;258(2):792–795. [PubMed] [Google Scholar]
  13. Maudgal P. C., De Clercq E., Descamps J., Missotten L. Comparative evaluation of BVDU ((E)-5-(2-bromovinyl)-2'-deoxyuridine) in the treatment of experimental herpes simplex keratitis in rabbits. Bull Soc Belge Ophtalmol. 1979;186:109–118. [PubMed] [Google Scholar]
  14. Maudgal P. C., De Clercq E., Descamps J., Missotten L., Wijnhoven J. Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine. Arch Ophthalmol. 1982 Apr;100(4):653–656. doi: 10.1001/archopht.1982.01030030655027. [DOI] [PubMed] [Google Scholar]
  15. Maudgal P. C., Missotten L., De Clercq E., Descamps J., De Meuter E. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216(4):261–268. doi: 10.1007/BF00455033. [DOI] [PubMed] [Google Scholar]
  16. Maudgal P. C., Uyttebroeck W., De Clercq E., Missotten L. Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine. Arch Ophthalmol. 1982 Aug;100(8):1337–1340. doi: 10.1001/archopht.1982.01030040315025. [DOI] [PubMed] [Google Scholar]
  17. Maudgal P. C., Verbruggen A. M., De Clercq E., Busson R., Bernaerts R., de Roo M., Ameye C., Missotten L. Ocular penetration of (125I)IVDU, a radiolabeled analogue of bromovinyldeoxyuridine. Invest Ophthalmol Vis Sci. 1985 Jan;26(1):45–49. [PubMed] [Google Scholar]
  18. Shigeta S., Yokota T., Iwabuchi T., Baba M., Konno K., Ogata M., De Clercq E. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis. 1983 Mar;147(3):576–584. doi: 10.1093/infdis/147.3.576. [DOI] [PubMed] [Google Scholar]
  19. Sundmacher R., Cantell K., Neumann-Haefelin D. Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet. 1978 Sep 23;2(8091):687–687. doi: 10.1016/s0140-6736(78)92809-x. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES